» Articles » PMID: 18703607

PET Changes Management and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2008 Aug 16
PMID 18703607
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: The aims of our study were to examine the impact of PET in changing management in patients with proven or suspected colorectal cancer recurrence and to assess the impact of management change on disease-free survival.

Methods: Symptomatic patients with a residual structural lesion suggestive of recurrent tumor (group A) or patients with pulmonary or hepatic metastases considered to be potentially resectable (group B) underwent PET scans. Pre-PET management plans were documented by referring clinicians unaware of the PET results, and follow-up to 12 mo was performed to determine actual management and clinical outcomes.

Results: A total of 191 patients (118 men and 73 women; mean age, 66 y) were studied. PET detected additional sites of disease in 48.4% of patients in group A and in 43.9% of patients in group B. A change in planned management was documented in 65.6% of group A and in 49.0% of group B patients. These management plans were implemented in 96% of patients. Follow-up data in group A showed progressive disease in 60.5% of patients with additional lesions detected by PET, compared with conventional imaging, and in 36.2% of patients with no additional lesions detected by PET (P=0.04). In group B, progressive disease was identified in 65.9% of patients with additional lesions detected by PET and in 39.2% of patients with no additional lesions detected by PET (P=0.01). PET also provided valuable prognostic information on patients stratified into curative- or palliative-intent groups.

Conclusion: These data demonstrate the significant impact of PET on management and outcomes in patients with suspected recurrent colorectal cancer.

Citing Articles

Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates.

Chen B, Ojha D, Toyonaga T, Tong J, Pracitto R, Thomas M Eur J Nucl Med Mol Imaging. 2023; 50(7):2081-2099.

PMID: 36849748 DOI: 10.1007/s00259-023-06162-y.


Disparities in access to cancer diagnostics in ASEAN member countries.

Alberto N, Alberto I, Puyat C, Antonio M, Ho F, Dee E Lancet Reg Health West Pac. 2023; 32:100667.

PMID: 36785859 PMC: 9918780. DOI: 10.1016/j.lanwpc.2022.100667.


Tailoring the clinical management of colorectal cancer by F-FDG PET/CT.

Shi Y, Wang M, Zhang J, Xiang Z, Li C, Zhang J Front Oncol. 2023; 12:1062704.

PMID: 36620584 PMC: 9814158. DOI: 10.3389/fonc.2022.1062704.


Impact of F-FDG PET/CT on treatment of patients with differentiated thyroid carcinoma, negative I whole body scan and elevated serum thyroglobulin.

Boktor R, Lee S, Berlangieri S, Scott A Asia Ocean J Nucl Med Biol. 2022; 10(1):20-27.

PMID: 35083346 PMC: 8742852. DOI: 10.22038/AOJNMB.2021.58276.1406.


Imaging biomarkers for evaluating tumor response: RECIST and beyond.

Ko C, Yeh L, Kuo Y, Chen J Biomark Res. 2021; 9(1):52.

PMID: 34215324 PMC: 8252278. DOI: 10.1186/s40364-021-00306-8.